Articles On Arc Exploration (ASX:ARX)
Title | Source | Codes | Date |
---|---|---|---|
Discovering 3 Hidden Gems in the Australian Market with Strong Growth Potential
Highlights GR Engineering Services GNG shows impressive earnings growth, with a debt-free balance sheet. Polynovo PNV presents a compelling opportunity in wound care, despite recent price fluctuations. Aroa Biosurgery ARX delivers str... |
Kalkine Media | ARX | 4 days ago |
Long Shortz with Aroa Biosurgery: Plenty of drivers into profitability for H2 FY25
Stockhead’s Sarah Hughan sits down with Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward to get the short end of the long story on the company’s latest news. The soft tissue repair products company has released its half yearly report... |
Stockhead | ARX | 5 days ago |
2 small cap ASX stocks with big price targets
If you have a higher than average tolerance for risk, then it could be worth considering a few small cap ASX stocks for a balanced portfolio. That's because the potential returns on offer at the small end of the market can be material. Thou... |
Motley Fool | ARX | 1 week ago |
Aroa product revenue up 27pc as Myriad sales drive growth
Aroa Biosurgery product revenue up 27% to NZ$39.1 million on constant currency basis in H1 FY25 Myriad sales surge 45% in H1 FY25, accounting for 38% of total sales and 72% of direct sales mix during half Aroa expects to be operating cashf... |
Stockhead | ARX | 1 week ago |
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7% Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate... |
Stockhead | ARX | 2 weeks ago |
Long Shortz with Aroa Biosurgery: Puzzle pieces coming together for success in H2 FY25
Stockhead’s Sarah Hughan sits down with Aroa Biosurgery’s (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The company’s biomaterial ECM technology aims to improve the rate and qualit... |
Stockhead | ARX | 1 month ago |
Closing Bell: ASX dips with MinRes and Viva tumbling; but Prodigy Gold hits jackpot
The ASX fell on new expectations for rate cuts All 11 ASX sectors fell, with real estate and healthcare hit hardest MinRes and Viva Energy dropped, Prodigy Gold rose 50pc The ASX slid by 1.66% from near record highs in a broad sell-o... |
Stockhead | ARX | 1 month ago |
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so As the end-of-October quarterly reporting... |
Stockhead | ARX | 1 month ago |
Aroa looks to capitalise on growing US wound care market
Aroa looks to capitalise on growing US wound-care market forecast to reach US$13 billion by 2034 Company is continuing to expand clinical evidence supporting efficacy of its ECM products Growing prevalence of chronic conditions like diabe... |
Stockhead | ARX | 1 month ago |
Health Kick Podcast: Aroa sets sights on sales growth in FY25
Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Brian Ward, founder and CEO at Aroa Biosurgery (ASX:ARX). Aroa was founded in 2008 by... |
Stockhead | ARX | 2 months ago |
WTF with ARX: Unlocking the power of regenerative healing
What is regenerative healing? Why are such healing products used? And where does AROA sits in the greater regenerative healing market? Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward joins the Stockhead TV studio to investigate thes... |
Stockhead | ARX | 2 months ago |
WTF with ARX: Unlocking the power of regenerative healing
What is regenerative healing? Why are such healing products used? And where does AROA sits in the greater regenerative healing market? Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward joins the Stockhead TV studio to investigate thes... |
Stockhead | ARX | 2 months ago |
Experts name 2 small cap ASX stocks to buy for big returns
Given the strong potential returns on offer at the small end of the market, it could be worth adding a few small cap ASX stocks to a balanced investment portfolio if you have a high risk tolerance. But which small caps could be top options... |
Motley Fool | ARX | 2 months ago |
Closing Bell: Tech, Miners fuel ASX winning run; but Yancoal sinks 14pc after dividend halt
ASX 200 nears 8,000 points, boosted by mining stocks Monadelphous and Baby Bunting rose; Yancoal and Dexus fell RBA considered lifting rates in August, minutes revealed The S&P/ASX 200 index rose by 0.2% to finish near 8,000 points... |
Stockhead | ARX | 3 months ago |
Aroa advances clinical evidence for soft tissue repair products
Aroa focused on expanding clinical evidence to support use of its ECM products in soft tissue repair Aroa expands Myriad Registry, the company’s largest prospective study to date Interim results of Symphony for complex non-healing diabetic... |
Stockhead | ARX | 3 months ago |
ScoPo’s Powerplays: ASX health stocks rise as Pro Medicus again hit the ball out of the park”
ASX health stocks rise 0.8% past five days as broader market lifts 3.7% Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24 CSL falls on FY24 results but Morgans still bullish on ASX’s largest h... |
Stockhead | ARX | 3 months ago |
Investors’ sneak peek at biotech’s bright future
The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors Day one focus on new opportunities, finding the next blockbuster drug and re... |
Stockhead | ARX | 4 months ago |
Bell Potter names the best ASX healthcare stocks to buy in FY25
Looking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX shares listed below. They have just been tipped as Bell Potter's top healthcare stocks to buy now: Aroa Biosurgery Ltd (ASX: ARX) Aroa Biosu... |
Motley Fool | ARX | 5 months ago |
Guess which small cap ASX stock could rise 50% in a 'transformational year'
If you're not averse to investing at the small side of the market, then it could be worth checking out Aroa Biosurgery Ltd (ASX: ARX). That's because analysts at Bell Potter believe the small cap ASX stock could rise materially from current... |
Motley Fool | ARX | 5 months ago |
Sheep-derived products propel Aroa’s global growth in soft tissue regeneration
AROA Biosurgery continues to expand its product line in regenerative tissue repair on back of positive clinical results Using ovine forestomach matrix, Aroa’s ECM technology offers top-tier regenerative performance at an attractive price p... |
Stockhead | ARX | 5 months ago |
ScoPo’s Powerplays: ASX health stocks fall as Sonic cuts FY24 profit guidance
ASX health stock fall in past five days along with broader markets Sonic Healthcare cuts FY24 profit guidance, citing costs pressures and currency headwinds Aroa Biosurgery FY24 results in line with guidance with total revenue up 12% yoy... |
Stockhead | ARX | 6 months ago |
Long Shortz with AROA Biosurgery: Delighted with full year results on Myriad of sales
Stockhead’s Sarah Hughan sits down with AROA Biosurgery (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The soft-tissue regeneration company released its FY24 financial results with... |
Stockhead | ARX | 6 months ago |
Closing Bell: Sierra Nevada jumps 80pc on drilling plans; Ethereum rallies amid ETF whispers
Tech stocks surged on ASX today, offset by losses in Mining stocks Gold and copper hit all-time highs Ethereum on the rise on rumours of ETF approvals in the US The ASX 200 closed around -0.15% lower on Tuesday, as gains in Tech stocks... |
Stockhead | ARX | 6 months ago |
Aroa meets guidance, aims for cashflow positivity in FY25
Soft tissue repair company Aroa Biosurgery FY24 revenue grows 12% yoy to NZ$69.1 million Myriad revenue up 73% to NZ$23.3 million Aroa focused on delivering positive operating cashflows in FY25 Special Report: Soft tissue repair company... |
Stockhead | ARX | 6 months ago |
Aroa Biosurgery posts steady Q4 result, progresses towards profitability in FY25
Positive net cash inflows from operations of NZ$300k, exceed Q4 breakeven expectations Strong cash receipts from customers of NZ$18 million, reflect continued increase in Myriad and OviTex/OviTex PRS sales ARX reduces quarterly cash burn b... |
Stockhead | ARX | 7 months ago |
Closing Bell: Lithium stocks flash green; suitor lobs bid for Sihayo Gold
The ASX inched higher on Tuesday ahead of the Fed’s rates call Lithium stocks flashed green today Amazon, CocaCola, Eli Lilly to report earnings later tonight The ASX200 edged cautiously higher by +0.35% on Tuesday on the back of a Wall... |
Stockhead | ARX | 7 months ago |
3 ASX healthcare shares outperforming on quarterly updates
S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio... |
Motley Fool | ARX | 7 months ago |
Aroa Biosurgery targets sales growth and operations cash flow positivity in FY25
Aroa Biosurgery focuses on transitioning operations to cashflow positive in FY25 US distribution partner TELA Bio reports strong growth to flow through to Aroa Biotech making strong progress on clinical trials and new product lines Soft... |
Stockhead | ARX | 8 months ago |
Closing Bell: ASX loses its bottle, but Gold50 shows some Gallium to advance 50pc
The ASX200 has ended Friday down 0.15pc, but ends week higher Property and Healthcare gains offset by Resources losses Small Caps led by Gold50 Wall Street hit more record highs on Thursday in New York, the Australian market on Friday,... |
Stockhead | ARX | 8 months ago |
Long Shortz with AROA Biosurgery: A chance at a smoother recovery from a Mastectomy? Thanks Enivo
Stockhead’s Ashtyn Hiron sits down with AROA Biosurgery (ASX:ARX) CEO Dr. Brian Ward to get the short end of the long story on the company’s latest news. Aroa Biosurgery’s Enivo system may reduce secondary complications in mastectomies, wit... |
Stockhead | ARX | 9 months ago |
ScoPo’s Powerplays: ASX health stocks up as Cochlear upgrades earnings guidance
ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue CSL to report half year results next week with b... |
Stockhead | ARX | 9 months ago |
In Case You Missed It: AI-aged care deal, EV bank loans and some rare earths
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today. ICYMI Leade... |
Stockhead | ARX | 1 year ago |
‘Fundamentals for success in place’: Myriad drives growth as AROA reports strong first half
AROA reports 80% increase in sales of high-margin Myriad in H1 FY24 TELA Bio’s sales of OviTex and OviTex PRS increase 37% during H1 FY24 on pcp Full-year FY24 guidance has been updated Special Report: Aroa Biosurgery released strong... |
Stockhead | ARX | 1 year ago |
REPORT: ASX wound care is rapidly becoming an ‘exciting subsector’
Morgans releases its ASX wound care report seeing value in Aroa Biosurgery, Avita Medical and PolyNovo Global wound care market is estimated to grow at a CAGR of 5.9% to reach US$28.6 billion by 2028 ASX wound care companies head towards p... |
Stockhead | ARX | 1 year ago |
Aroa maintains FY24 revenue growth forecast at 30pc after strong Q2
Aroa Biosurgery maintains product revenue guidance for FY24, up 25-30% on FY23 Company’s US commercial operations perform particularly well during Q2 FY24 Myriad sales increase to 67% of company’s direct sales mix in Q2 from 50% in Q2 FY23... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)
ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp... |
Stockhead | ARX | 1 year ago |
Wound wizard Aroa forecasts 30pc annual growth as it transitions to ‘highly profitable business’
Aroa Biosurgery forecasts business growth of up to 30% annually with product revenue guidance of NZ$73-$76 million in FY24 New study highlights positive outcomes using Myriad Matrix and Myriad Morcells in complex traumatic wounds Aroa focu... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: Who fancies a ‘MedWalk intervention’? Oh, and ASX healthcare stocks can’t catch a break
ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: Should have stayed in bed as ASX stocks fall but Neuren makes S&P ASX 200
ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: ASX health stock fall but hold onto your hat for reporting season
ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: Mesoblast sinks Health sector, and how to live 24 years longer
ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product ImpediMed falls after calls for board spill with discontent following cap raise Healthcare... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: ASX health stocks rise as Volpara records third quarter of positive cashflow
ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: ASX health stocks… could be worse
ASX health stocks outperforming the broader market but remain flattish for week Several ASX health plays undertaking capital raising with more expected in H2 CY23 Micro-X successfully tests its Argus bomb detection unit opening door to US$... |
Stockhead | ARX | 1 year ago |
Why Aroa Biosurgery, Bank of Queensland, Champion Iron, and Terracom shares are falling
The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Tuesday. In afternoon trade, the benchmark index is down 1.4% to 7,110.3 points. Four ASX shares that are falling more than most today are listed below. Hereâs why they are... |
Motley Fool | ARX | 1 year ago |
Aroa Biosurgery [ASX:ARX] Posts FY23 Results and Shares FY24 Outlook
Biotech Aroa has released its audited results for the 2023 financial year, hitting targets and achieving its expectations. The company looks ahead with a positive perspective on FY24, with the group providing new guidance today. The post A... |
MoneyMorning | ARX | 1 year ago |
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year After a challenging 2022, we are finally s... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news
ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm... |
Stockhead | ARX | 1 year ago |
Morgans says these small cap ASX healthcare shares are buys with 50% upside
There could be big returns lurking at the small end of town according to analysts at Morgans. Here’s what it is expecting from these small cap ASX healthcare shares: Aroa Biosurgery Ltd (ASX: ARX) The first small cap ASX healthcare share... |
Motley Fool | ARX | 1 year ago |
ASX Health Stocks: Pharmaxis and Aroa lift on FDA news, Cynata to commence Phase 2 trial
Pharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata gets Australian Ethics approval to commence Phase 2 Pharmaxis to widen Phase 2 trial after FDA feedback Fibrotic diseases specialist Pharm... |
Stockhead | ARX | 1 year ago |
ScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines update
ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema EBR Systems to release top line results at cardiac conference Heart Rhythm... |
Stockhead | ARX | 1 year ago |